National Health Commission issues new version of clinical application guidelines for novel anti-tumor drugs

In order to further regulate the clinical application of new anti-tumor drugs, the National Health Commission today released the "Guiding Principles for the Clinical Application of New Anti-tumor Drugs". The new anti-tumor drugs mentioned in the "Guiding Principles" refer to small molecule targeted drugs, large molecule monoclonal antibody drugs, and cell therapy suitable for anti-tumor treatment, etc. The application of anti-tumor drugs involves multiple clinical disciplines. The rational use of anti-tumor drugs is the key to improving efficacy, reducing the incidence of adverse reactions, and rational use of health resources. The clinical application of anti-tumor drugs needs to consider factors such as drug availability, patient treatment willingness, disease prognosis, and medication safety. The rationality of the clinical application of anti-tumor drugs is based on two aspects: whether there are indications for the use of anti-tumor drugs, and comprehensive considerations of safety, efficacy, economy, and suitability.